Differences of Serum Ratio MMP-9/TIMP-1 in ST-Elevation Myocardial Infarction (STEMI) and Non ST-Elevation Acute Coronary Syndrome (NSTEACS)
Background: Differences between the pathogenesis of ST-Elevation Myocardial infarction (STEMI) and Non-ST Elevation Acute Coronary Syndrome (NSTE-ACS) had yet unknown. Matrix metalloproteinase-9 (MMP-9) as the matrix degradation enzyme secreted by inflammatory cells play a role in the pathogenesis o...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Indonesian Heart Association
2014-03-01
|
| Series: | Majalah Kardiologi Indonesia |
| Subjects: | |
| Online Access: | http://ijconline.id/index.php/ijc/article/view/337 |
| _version_ | 1819206246803177472 |
|---|---|
| author | Basuki Rahmat Lucia Kris Dinarti Irmalita I Budi Yuli Setianto |
| author_facet | Basuki Rahmat Lucia Kris Dinarti Irmalita I Budi Yuli Setianto |
| author_sort | Basuki Rahmat |
| collection | DOAJ |
| description | Background: Differences between the pathogenesis of ST-Elevation Myocardial
infarction (STEMI) and Non-ST Elevation Acute Coronary Syndrome
(NSTE-ACS) had yet unknown. Matrix metalloproteinase-9 (MMP-9) as the
matrix degradation enzyme secreted by inflammatory cells play a role in the
pathogenesis of plaque rupture. MMP-9 proteolytic activity is inhibited by
specific inhibitors of the Tissue Inhibitor of metalloproteinase-1 (TIMP-1).
MMP-9/TIMP-1 ratio describes the actual proteolytic activity of MMP-9.
This ratio may distinguish the pathogenesis of STEMI and NSTE-ACS.
Objective: To examine the difference serum level ratio MMP-9/TIMP-1 in
patients with STEMI and NSTE-ACS.
Methods and subjects: This is a cross-sectional study which recruits patients
consecutively with ACS admitted to ICCU of Dr. Sardjito General Hospital Yogyakarta
within 24 h onset. Acute infection, chronic inflammation, acute stroke,
kidney failure requiring renal replacement therapy, chronic heart failure, liver cirrhosis,
acute exacerbation of COPD and pneumonia, thromboembolic disease,
malignancy, pregnancy and the use of steroids and steroid anti-inflammatory
drugs are excluded. Serum levels of MMP-9 and TIMP-1 examined using the
method of sandwich enzyme-linked immunosorbent assay (ELISA).
Results: The total of 60 subjects with STEMI patients 31 (51.7%) and NSTEACS
29 (48.3%). Level of serum MMP-9/TIMP-1 ratio is significantly higher in
STEMI compared to NSTE-ACS (1.106 0.065 vs. 1.046 0.057, p <0.001).
MMP-9/TIMP-1 ratio in serum is an independent factor for STEMI (p = 0.003)
followed by blood sugar level (p = 0.013) and MMP-9 (p = 0.033). Interestingly,
patients with serum MMP-9/TIMP-1 ratio> 1.0639 has a prevalence risk
of 1.7 times having STEMI (p = 0.039; KI95% from 1.040 to 8.508). Levels of
serum MMP-9/TIMP-1 ratio significantly higher in STEMI compared to NSTEMI
group (p = 0.003) and in the STEMI and UAP group (0.026), but did not differ
significantly in NSTEMI and UAP group (p = 0.045).
Conclusion: High levels of serum MMP-9/TIMP-1 ratio in patients with
STEMI than NSTEACS may explain the role of serum MMP-9/TIMP-1 ratio
in differentiating the pathogenesis of STEMI and NSTE-ACS.
(J Kardiol Indones. 2013;34:160-6) |
| first_indexed | 2024-12-23T05:04:33Z |
| format | Article |
| id | doaj.art-7340e787d8b94419898eb23e96bde7d4 |
| institution | Directory Open Access Journal |
| issn | 0126-3773 2620-4762 |
| language | English |
| last_indexed | 2024-12-23T05:04:33Z |
| publishDate | 2014-03-01 |
| publisher | Indonesian Heart Association |
| record_format | Article |
| series | Majalah Kardiologi Indonesia |
| spelling | doaj.art-7340e787d8b94419898eb23e96bde7d42022-12-21T17:59:08ZengIndonesian Heart AssociationMajalah Kardiologi Indonesia0126-37732620-47622014-03-0134310.30701/ijc.v34i3.337Differences of Serum Ratio MMP-9/TIMP-1 in ST-Elevation Myocardial Infarction (STEMI) and Non ST-Elevation Acute Coronary Syndrome (NSTEACS)Basuki Rahmat0Lucia Kris Dinarti1Irmalita I2Budi Yuli Setianto3Department of Cardiology and Vascular Medicine, Faculty of Medicine, University of Mataram.Department of Cardiology and Vascular Medicine, Faculty of Medicine, University of Gadjah MadaDepartment of Cardiology and Vascular Medicine, Faculty of Medicine, University of IndonesiaDepartment of Cardiology and Vascular Medicine, Faculty of Medicine, University of Gadjah MadaBackground: Differences between the pathogenesis of ST-Elevation Myocardial infarction (STEMI) and Non-ST Elevation Acute Coronary Syndrome (NSTE-ACS) had yet unknown. Matrix metalloproteinase-9 (MMP-9) as the matrix degradation enzyme secreted by inflammatory cells play a role in the pathogenesis of plaque rupture. MMP-9 proteolytic activity is inhibited by specific inhibitors of the Tissue Inhibitor of metalloproteinase-1 (TIMP-1). MMP-9/TIMP-1 ratio describes the actual proteolytic activity of MMP-9. This ratio may distinguish the pathogenesis of STEMI and NSTE-ACS. Objective: To examine the difference serum level ratio MMP-9/TIMP-1 in patients with STEMI and NSTE-ACS. Methods and subjects: This is a cross-sectional study which recruits patients consecutively with ACS admitted to ICCU of Dr. Sardjito General Hospital Yogyakarta within 24 h onset. Acute infection, chronic inflammation, acute stroke, kidney failure requiring renal replacement therapy, chronic heart failure, liver cirrhosis, acute exacerbation of COPD and pneumonia, thromboembolic disease, malignancy, pregnancy and the use of steroids and steroid anti-inflammatory drugs are excluded. Serum levels of MMP-9 and TIMP-1 examined using the method of sandwich enzyme-linked immunosorbent assay (ELISA). Results: The total of 60 subjects with STEMI patients 31 (51.7%) and NSTEACS 29 (48.3%). Level of serum MMP-9/TIMP-1 ratio is significantly higher in STEMI compared to NSTE-ACS (1.106 0.065 vs. 1.046 0.057, p <0.001). MMP-9/TIMP-1 ratio in serum is an independent factor for STEMI (p = 0.003) followed by blood sugar level (p = 0.013) and MMP-9 (p = 0.033). Interestingly, patients with serum MMP-9/TIMP-1 ratio> 1.0639 has a prevalence risk of 1.7 times having STEMI (p = 0.039; KI95% from 1.040 to 8.508). Levels of serum MMP-9/TIMP-1 ratio significantly higher in STEMI compared to NSTEMI group (p = 0.003) and in the STEMI and UAP group (0.026), but did not differ significantly in NSTEMI and UAP group (p = 0.045). Conclusion: High levels of serum MMP-9/TIMP-1 ratio in patients with STEMI than NSTEACS may explain the role of serum MMP-9/TIMP-1 ratio in differentiating the pathogenesis of STEMI and NSTE-ACS. (J Kardiol Indones. 2013;34:160-6)http://ijconline.id/index.php/ijc/article/view/337The ratio of MMP-9/TIMP-1ST-Elevation Myocardial infarctNon-ST Elevation Acute Coronary Syndrome. |
| spellingShingle | Basuki Rahmat Lucia Kris Dinarti Irmalita I Budi Yuli Setianto Differences of Serum Ratio MMP-9/TIMP-1 in ST-Elevation Myocardial Infarction (STEMI) and Non ST-Elevation Acute Coronary Syndrome (NSTEACS) Majalah Kardiologi Indonesia The ratio of MMP-9/TIMP-1 ST-Elevation Myocardial infarct Non-ST Elevation Acute Coronary Syndrome. |
| title | Differences of Serum Ratio MMP-9/TIMP-1 in ST-Elevation Myocardial Infarction (STEMI) and Non ST-Elevation Acute Coronary Syndrome (NSTEACS) |
| title_full | Differences of Serum Ratio MMP-9/TIMP-1 in ST-Elevation Myocardial Infarction (STEMI) and Non ST-Elevation Acute Coronary Syndrome (NSTEACS) |
| title_fullStr | Differences of Serum Ratio MMP-9/TIMP-1 in ST-Elevation Myocardial Infarction (STEMI) and Non ST-Elevation Acute Coronary Syndrome (NSTEACS) |
| title_full_unstemmed | Differences of Serum Ratio MMP-9/TIMP-1 in ST-Elevation Myocardial Infarction (STEMI) and Non ST-Elevation Acute Coronary Syndrome (NSTEACS) |
| title_short | Differences of Serum Ratio MMP-9/TIMP-1 in ST-Elevation Myocardial Infarction (STEMI) and Non ST-Elevation Acute Coronary Syndrome (NSTEACS) |
| title_sort | differences of serum ratio mmp 9 timp 1 in st elevation myocardial infarction stemi and non st elevation acute coronary syndrome nsteacs |
| topic | The ratio of MMP-9/TIMP-1 ST-Elevation Myocardial infarct Non-ST Elevation Acute Coronary Syndrome. |
| url | http://ijconline.id/index.php/ijc/article/view/337 |
| work_keys_str_mv | AT basukirahmat differencesofserumratiommp9timp1instelevationmyocardialinfarctionstemiandnonstelevationacutecoronarysyndromensteacs AT luciakrisdinarti differencesofserumratiommp9timp1instelevationmyocardialinfarctionstemiandnonstelevationacutecoronarysyndromensteacs AT irmalitai differencesofserumratiommp9timp1instelevationmyocardialinfarctionstemiandnonstelevationacutecoronarysyndromensteacs AT budiyulisetianto differencesofserumratiommp9timp1instelevationmyocardialinfarctionstemiandnonstelevationacutecoronarysyndromensteacs |